Provider review
IVIM Health review: pricing, pharmacy, and evidence status
Released: · Last reviewed: · By Dr. Parmis
IVIM Health offers GLP-1 medications through telehealth. Every price, credential and pharmacy claim below is labeled by evidence status and read date.
IVIM Health's lowest price on file is $140/month ("Starting at" $65 a month plus a $75 monthly program fee), read November 20, 2026 on its own page. It does not name a dispensing pharmacy. On November 20, 2026 it scored 53.8/100 on GLP Ranked's v4.1 rubric, #10 of 15.
Rank and score
IVIM Health scores 53.8 of 100, #10 of 15 scored programs (November 20, 2026). The table shows every sub-check, the points earned and why; the methodology explains each one.
| ID | Category | Sub-check | Points | Note |
|---|---|---|---|---|
| PT1 | Pricing transparency | Drug price printed on the program's own page, read in the November 20, 2026 re-read | 5 of 5 | |
| PT2 | Pricing transparency | Price includes medication and care, or every required fee is printed beside it (2 if the program's own figures disagree) | 5 of 5 | |
| PT3 | Pricing transparency | Price at every dose knowable: same price at every dose, or a full dose ladder | 0 of 5 | 'starting at' prices |
| PT4 | Pricing transparency | Plan term and billing interval stated (2 if the program's own pages disagree) | 0 of 5 | program runs to a fixed end date; its length is not printed on the page read |
| CO1 | Clinical oversight | Prescribing medical group named (9), network label (5), physician executive only (3), arrangement described (2) | 3 of 9 | |
| CO2 | Clinical oversight | Prescribers' licensure or certification stated | 3 of 3 | |
| CO3 | Clinical oversight | Clinical lead (medical director or chief medical officer) named with credential | 3 of 3 | |
| PH1 | Pharmacy transparency | Dispensing pharmacy named (10), class described but not named (4), described only (2); brand-only programs whose pages say prescriptions go to the pharmacy you choose (10) | 10 of 10 | medication-safety page names six pharmacies, including Empower Pharmacy |
| PH2 | Pharmacy transparency | Pharmacy class (503A/503B) or licensure stated; brand-only programs that send prescriptions to your chosen pharmacy (5) | 0 of 5 | |
| SU1 | Support | Two or more contact channels published (4), one (2) | 2 of 4 | |
| SU2 | Support | How to cancel is stated | 3 of 3 | |
| SU3 | Support | Refund terms are stated (any stated condition under which money is refunded or credited) | 3 of 3 | |
| RD1 | Regulatory disclosure | Compounded products described as not FDA-approved; brand-only programs (5) | 5 of 5 | |
| RD2 | Regulatory disclosure | No open FDA warning letter in FDA's index (read November 20, 2026) | 0 of 5 | FDA warning letter 721816, February 20, 2026; no close-out posted |
| AC1 | Accessibility | Where it operates stated clearly (4); vague or conflicting statements (2) | 2 of 4 | |
| AC2 | Accessibility | Payment beyond a card stated (HSA/FSA or pay-later) | 3 of 3 | |
| AC3 | Accessibility | Can start month to month without a multi-month commitment | 0 of 3 | program runs to a fixed end date |
| AN | Total annual cost | semaglutide, 12 months: $1,680 (12 × ($65 'starting at' + $75 program fee)), a minimum at half weight; benchmark $1,140 | 6.8 of 20 | 20 × benchmark ÷ cost |
| Total | 53.8 of 100 | |||
FDA record: FDA warning letter 721816, dated February 20, 2026 (False & Misleading Claims/Misbranded (Telehealth)). FDA's index showed no close-out letter when read on November 20, 2026. Under sub-check RD2 an open letter removes 5 points, for every program alike.
Strengths and limitations
Drawn from the sub-checks above, as read November 20-21, 2026.
- Strength: Drug price printed on the program's own page, read in the November 20, 2026 re-read.
- Strength: Price includes medication and care, or every required fee is printed beside it.
- Strength: Prescribers' licensure or certification stated.
- Strength: Clinical lead.
- Limitation: Price at every dose knowable: same price at every dose, or a full dose ladder: 0 of 5 ('starting at' prices).
- Limitation: Plan term and billing interval stated: 0 of 5 (program runs to a fixed end date; its length is not printed on the page read).
- Limitation: Prescribing medical group named: 3 of 9.
- Limitation: Pharmacy class: 0 of 5.
- Limitation: Two or more contact channels published: 2 of 4.
- Limitation: No open FDA warning letter in FDA's index: 0 of 5 (FDA warning letter 721816, February 20, 2026; no close-out posted).
- Limitation: Where it operates stated clearly: 2 of 4.
- Limitation: Can start month to month without a multi-month commitment: 0 of 3 (program runs to a fixed end date).
- Limitation: total annual cost scores 6.8 of 20.
Pricing by plan
| Medication | Formulation | Plan | Price | Source | Evidence |
|---|---|---|---|---|---|
| tirzepatide | compounded injectable | "Starting at" $117 a month plus a $75 monthly program fee | $192/mo | provider page · read 2026-11-20 | Provider reported |
| semaglutide | compounded injectable | "Starting at" $65 a month plus a $75 monthly program fee | $140/mo | provider page · read 2026-11-20 | Provider reported |
"Provider reported" means the figure comes from the company's own site or intake flow and has not been independently corroborated by GLP Ranked.
Clinical model
Physician executive only: “Dr. Jessica Duncan, MD, DABOM Chief Medical Officer” (www.ivimhealth.com, read 2026-11-10)
Accreditation: we have not verified any accreditation or certification claim for IVIM Health against the issuing body. If a program cites one (for example LegitScript), check the issuer's public lookup before you rely on it.
Pharmacy & compliance
Its medication-safety page names six compounding pharmacies with phone numbers: Empower Pharmacy (Houston, TX), Hallandale Pharmacy (Fort Lauderdale, FL), SBH Medical (Columbus, OH), Enovex Compounding Pharmacy (Los Angeles, CA), The Pharmacy Hub (Miami, FL) and Olympia Pharmacy (Orlando, FL); no pharmacy class is stated (read 2026-11-21) Pharmacy transparency is worth 15 of 100 points under our v4.1 rubric.
State availability
State-by-state availability is not independently verified.
Who this suits — and who it doesn't
IVIM Health may suit patients who want a standard-dose program and are comfortable proceeding without a named dispensing pharmacy disclosed up front.It is a weaker fit for patients who need written proof of pharmacy accreditation before paying; ask the company for it.
Terms to check before you pay: whether cancellation and refund terms were found on its pages is recorded in sub-checks SU2 and SU3 above (read November 21, 2026); published support response times: not published.
Sources
- FDA warning letter 721816 (False & Misleading Claims/Misbranded (Telehealth)) — Regulator letter, captured 2026-11-20
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current October 1, 2026) — Regulator page, captured 2026-11-20
- FDA: Compounding: Inspections, Recalls, and other Actions (content current October 22, 2026) — Regulator list, captured 2026-11-21
Cite this page
GLP Ranked. "IVIM Health review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/ivim-health/
GLP Ranked. "IVIM Health review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/ivim-health/